Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

MAY 31 2023

Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference

MORRISVILLE, N.C. , May 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that Mr. Roger Jeffs , Chief Executive Officer, and Mr. Michael Kaseta , Chief Financial Officer, will provide an update on the Company's business during a fireside chat at the
MAY 19 2023

Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference

MORRISVILLE, N.C. , May 19, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder at the 2023 American Thoracic Society (ATS)

btn News